Genelux Co. (NASDAQ:GNLX) Short Interest Update

Genelux Co. (NASDAQ:GNLX) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 2,030,000 shares, a growth of 8.0% from the March 31st total of 1,880,000 shares. Approximately 10.2% of the company’s shares are short sold. Based on an average daily volume of 137,300 shares, the days-to-cover ratio is currently 14.8 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on GNLX shares. HC Wainwright lowered their price target on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Benchmark restated a “speculative buy” rating and issued a $30.00 price target on shares of Genelux in a report on Wednesday, April 3rd.

Genelux Stock Up 5.5 %

GNLX stock opened at $3.28 on Thursday. The business has a 50-day moving average of $5.41 and a 200-day moving average of $10.31. Genelux has a fifty-two week low of $3.06 and a fifty-two week high of $40.98.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). On average, equities analysts predict that Genelux will post -0.81 EPS for the current fiscal year.

Insider Activity at Genelux

In related news, major shareholder Aladar Szalay sold 48,683 shares of the company’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $3.53, for a total value of $171,850.99. Following the completion of the sale, the insider now owns 1,322,862 shares in the company, valued at $4,669,702.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders sold 110,542 shares of company stock worth $380,574. 11.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Woodward Diversified Capital LLC boosted its position in shares of Genelux by 0.3% during the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock worth $6,983,000 after buying an additional 3,687 shares during the period. LifeSteps Financial Inc. boosted its position in Genelux by 26.6% during the first quarter. LifeSteps Financial Inc. now owns 44,309 shares of the company’s stock valued at $285,000 after purchasing an additional 9,301 shares during the last quarter. Clarity Capital Partners LLC acquired a new position in Genelux during the fourth quarter valued at approximately $364,000. Tower Research Capital LLC TRC boosted its position in Genelux by 216.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock valued at $41,000 after purchasing an additional 2,021 shares during the last quarter. Finally, Apollon Wealth Management LLC acquired a new position in Genelux during the fourth quarter valued at approximately $196,000. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.